Defeating stem cell tourism

Bibliography

• 1  Mason C: Regenerative medicine 2.0. Regen. Med.2(1),11–18 (2007).
  Google Scholar
• 2  Mason C: Regenerative medicine. The industry comes of age. Med. Device Technol.18(2),25–30 (2007).
  Medline CASGoogle Scholar
• 3  Mason C, Manzotti E: Regen: the industry responsible for cell-based therapies. Regen. Med.4(6),783–785 (2009).
  Google Scholar
• 4  ISSCR Guidelines for the Clinical Translation of Stem Cells. Curr. Protoc. Stem Cell Biol. Appendix 1:Appendix 1B (2009).
  Google Scholar
• 5  Hyun I, Lindvall O, Ahrlund-Richter L et al.: New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell3(6),607–609 (2008).
  Medline CASGoogle Scholar
• 6  Taylor PL, Barker RA, Blume KG et al.: Patients beware: commercialized stem cell treatments on the web. Cell Stem Cell7(1),43–49 (2010).
  Medline CASGoogle Scholar
• 7  Mason C, Manzotti E: Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Regen. Med.5(3),307–313 (2010).
  Google Scholar
• 8  Anderson KD: Targeting recovery: priorities of the spinal cord-injured population. J. Neurotrauma21(10),1371–1383 (2004).
  MedlineGoogle Scholar
• 9  Roach MJ, Frost FS, Creasey G: Social and personal consequences of acquired bowel dysfunction for persons with spinal cord injury. J. Spinal Cord Med.23(4),263–269 (2000).
  Medline CASGoogle Scholar
• 10  Kemp P: History of regenerative medicine: looking backwards to move forwards. Regen. Med.1(5),653–669 (2006).
  Google Scholar
• 11  Lindvall O, Kokaia Z: Prospects of stem cell therapy for replacing dopamine neurons in Parkinson’s disease. Trends Pharmacol. Sci.30(5),260–267 (2009).
  Medline CASGoogle Scholar
• 12  Stevenson A, Lindberg CA: New Oxford American Dictionary (3rd Edition). Oxford University Press, Oxford, UK; NY, USA (2010).
  Google Scholar
• 13  Coons SJ: The FDA’s critical path initiative: a brief introduction. Clin. Ther.31(11),2572–2573 (2009).
  MedlineGoogle Scholar
• 14  Lipsky MS, Sharp LK: From idea to market: the drug approval process. J. Am. Board Fam. Pract.14(5),362–367 (2001).
  Medline CASGoogle Scholar
• 15  Mehta SS: Commercializing Successful Biomedical Technologies: Basic Principles for the Development of Drugs, Diagnostics and Devices. Cambridge University Press, Cambridge, UK; NY, USA (2008).
  Google Scholar
• 16  Woodcock J: Interview with Janet Woodcock: progress on the FDA’s critical path initiative. Biomark. Med.3(6),671–673 (2009).
  Google Scholar
• 17  Deyo RA: Gaps, tensions, and conflicts in the FDA approval process: implications for clinical practice. J. Am. Board Fam. Pract.17(2),142–149 (2004).
  MedlineGoogle Scholar
• 18  Fleming TR: Surrogate endpoints and FDA’s accelerated approval process. Health Aff. (Millwood)24(1),67–78 (2005).
  MedlineGoogle Scholar
• 19  Freeman SN, Burke KA, Imoisili MA, Cote TR: The Orphan Drug Act and the Development of Stem Cell-Based Products for Rare Diseases. Cell Stem Cell7(3),283–287 (2010).
  Medline CASGoogle Scholar
• 20  Amariglio N, Hirshberg A, Scheithauer BW et al.: Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med.6(2),e1000029 (2009).
  MedlineGoogle Scholar
• 21  Thirabanjasak D, Tantiwongse K, Thorner PS: Angiomyeloproliferative lesions following autologous stem cell therapy. J. Am. Soc. Nephrol.21(7),1218–1222 (2010).
  MedlineGoogle Scholar
• 22  Mason C, Manzotti E: The Translation Cycle: round and round in cycles is the only way forward for regenerative medicine. Regen. Med.5(2),153–155 (2010).
  Google Scholar
• 23  von Tigerstrom B: Product regulation and the clinical translation of stem cell research. Stem Cell Rev.5(2),135–139 (2009).
  Google Scholar
• 24  Ratner M, Gura T: Off-label or off-limits? Nat. Biotechnol.26(8),867–875 (2008).
  Medline CASGoogle Scholar
• 25  Radley DC, Finkelstein SN, Stafford RS: Off-label prescribing among office-based physicians. Arch. Intern. Med.166(9),1021–1026 (2006).
  MedlineGoogle Scholar
• 26  Largent EA, Miller FG, Pearson SD: Going off-label without venturing off-course: evidence and ethical off-label prescribing. Arch. Intern. Med.169(19),1745–1747 (2009).
  MedlineGoogle Scholar
• 101  A closer look at stem cell treatments. ISSCR www.closerlookatstemcells.org
  Google Scholar
• 102  Critical Path 2010 Update. FDA www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ucm204289.htm
  Google Scholar
• 103  Fast Track, Accelerated Approval and Priority Review. FDA Link
  Google Scholar
• 104  Advanced Cell Technology‘s RPE Cells Granted Orphan Drug Status from FDA for Treatment of Stargardt’s Macular Dystrophy www.advancedcell.com/documents/0000/0226/03.02.10.pdf (Accessed 3 February 2010)
  Google Scholar
• 105  New Rules for Expanded Access to Investigational Drugs for Treatment Use and Charging for Investigational Drugs. FDA www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm177022.htm
  Google Scholar
• 106  FDA Expands Access to Investigational Drugs. FDA www.fda.gov/ForConsumers/ConsumerUpdates/ucm176845.htm
  Google Scholar
• 107  Access to Investigational Drugs Outside of a Clinical Trial (Expanded Access). FDA www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/AccesstoInvestigationalDrugs/ucm176098.htm
  Google Scholar
• 108  21 CFR Part 312 and 316 Charging for Investigational Drugs Under and Investigational New Drug Application; Expanded Access to Investigational Drugs for Treatment Use; Final Rules 13 August, 2009. FDA http://edocket.access.gpo.gov/2009/pdf/E9–19004.pdf
  Google Scholar
• 109  Expanded Access of Prochymal Infusion for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD. ClinicalTrial.gov http://clinicaltrials.gov/ct2/show/NCT00759018?term=prochymal&rank=4
  Google Scholar